Macquarie Downgrades CBOE (CBOE) - Shares Fall; Upgrades CME (CME) - Shares Rise
Tweet
Share
E-mailGet Alerts CBOE Hot Sheet
Price: $181.79 +1.34%
Rating Summary:
13 Buy, 15 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
13 Buy, 15 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
This morning Macquarie downgrades CBOE Holdings (Nasdaq: CBOE) from Outperform to Neutral and cut is price target by $2 to $32. Currently, shares are down $0.82 (-3.12%) to $25.43, which is still smack in the middle of its 52-wk range $21.55 - 29.77.
Also this morning, Macquarie upgraded CME Group (NYSE: CME) from Neutral to Outperform and maintained its $344 price target (which is still 40% above current value). Shares are up $4.51 (+1.87%) to $245.85. The 52-wk range is $235.23 - 327.98.
In a 52-wk chart, shares of CBOE have easily outperformed, adding almost 20%. Meanwhile, over the past year, CME has fallen about 25%.
Also this morning, Macquarie upgraded CME Group (NYSE: CME) from Neutral to Outperform and maintained its $344 price target (which is still 40% above current value). Shares are up $4.51 (+1.87%) to $245.85. The 52-wk range is $235.23 - 327.98.
In a 52-wk chart, shares of CBOE have easily outperformed, adding almost 20%. Meanwhile, over the past year, CME has fallen about 25%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
- Leerink Partners Upgrades Tandem Diabetes Care (TNDM) to Outperform
- Needham Downgrades HashiCorp Inc (HCP) to Hold
Create E-mail Alert Related Categories
Downgrades, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
